试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Aspiair GmbH
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer)CTIS2023-506975-83-00Aprogen Inc.720
进行中（未招募）
1 期
Pilot trial of single dose ilofotase alfa in hypophosphatasiaHypophosphatasiaMedDRA version: 20.1Level: PTClassification code: 10049933Term: Hypophosphatasia Class: 100000004850CTIS2023-503186-35-00AM-Pharma B.V.12
招募中
1 期
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent.MedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864GlioblastomaCTIS2023-506719-17-00ovartis Pharma AG55
进行中（未招募）
1 期
A Phase 1 relative bioavailability study in 14 healthy adult participants investigating the Arvisol® tablets to see whether its pharmacokinetic properties are similar to the reference drug which is a marketed oral soliton cannabidiol, named Epidiolex® CBD oral solution.Healthy volunteersMedDRA version: 26.0Level: LLTClassification code: 10088820Term: Clinical trial healthy volunteer Class: 100000004848CTIS2023-509862-39-00Echo Pharmaceuticals B.V.14
进行中（未招募）
1 期
A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOADCTIS2023-508363-79-00Alnylam Pharmaceuticals Inc.59